CLINICAL TRIALS PROFILE FOR QUESTRAN LIGHT

All Clinical Trials for Questran Light

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	Biomedical Foundation for Cardiovascular Research of Padova	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	Pfizer	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.
NCT01053065 ↗	The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study	Completed	University of Padova	N/A	1969-12-31	The impact on cardiovascular events achieved by statin therapy seems to be mostly attributable to the cholesterol-lowering effect with a highly debated contribution of the lipid-independent pleiotropic effects. However, a short-term benefit has been documented for patients treated with statins in acute coronary syndromes and other clinical settings. These observations strengthened the hypothesis of additional, so-called pleiotropic actions of statins. The investigators therefore sought to investigate how different lipid-lowering strategies (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of carotid plaque over a short-term period of three months. Specifically the investigators tried and dissect the LDL-C lowering impact on plaque cellular composition as compared to the lipid-independent contribution on plaque macrophage and smooth muscle cells.

Clinical Trial Conditions for Questran Light

Condition Name

Condition Name for Questran Light
Intervention	Trials
Healthy	2
DIABETES	2
Symptomatic Carotid Stenosis	1

Condition MeSH

Condition MeSH for Questran Light
Intervention	Trials
Graves Disease	1
Hematologic Neoplasms	1
Diabetic Neuropathies	1

Clinical Trial Locations for Questran Light

Trials by Country

Trials by Country for Questran Light
Location	Trials
United States	6
Malaysia	3
Chile	2
France	1
Italy	1

Trials by US State

Trials by US State for Questran Light
Location	Trials
California	2
Kentucky	2
North Carolina	1
Michigan	1

Clinical Trial Progress for Questran Light

Clinical Trial Phase

Clinical Trial Phase for Questran Light
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Questran Light
Clinical Trial Phase	Trials
Completed	5
Recruiting	2
Unknown status	1

Clinical Trial Sponsors for Questran Light

Sponsor Name

Sponsor Name for Questran Light
Sponsor	Trials
Louisville Metabolic and Atherosclerosis Research Center	2
National Cancer Institute (NCI)	2
City of Hope Medical Center	2

Sponsor Type

Sponsor Type for Questran Light
Sponsor	Trials
Other	14
Industry	6
NIH	2

Questran Light Market Analysis and Financial Projection

Last updated: February 10, 2026

What is the current status of clinical trials for Questran Light?

Questran Light, marketed as cholestyramine powder, is a bile acid sequestrant approved by the U.S. Food and Drug Administration (FDA) for lowering elevated LDL cholesterol in patients with hypercholesterolemia. As of 2023, the drug is approved for short-term use. It does not currently have active clinical trials listed on ClinicalTrials.gov that focus on new formulations, extended indications, or novel delivery methods.

There are no ongoing or recently completed clinical trials specifically investigating Questran Light’s safety or efficacy for new uses. Most research references focus on its established lipoprotein management role. The drug’s patent protection has expired, and no new patent filings for reformulations or new indications are noted.

What is the market landscape for Questran Light?

Questran Light operates within the niche of bile acid sequestrants, a class primarily composed of cholestyramine, colesevelam, and colestipol. It holds a fragment of the overall hyperlipidemia treatment market. The market is driven by increasing prevalence of cardiovascular disease, regulatory updates favoring lipid management, and generic availability.

Key market players:

• Praluent (alirocumab)
• Repatha (evolocumab)
• Lipitor (atorvastatin)
• Zetia (ezetimibe)
• The bile acid sequestrants, including Questran Light, are considered adjuncts or second-line therapies.

Market size and share:

• The global hyperlipidemia treatment market reached approximately USD 11.2 billion in 2022, with bile acid sequestrants accounting for an estimated 8-10% of the total.
• Questran Light’s market share is limited due to the availability of more modern or convenient lipid-lowering agents. It remains favored for certain patient sub-groups with intolerances or specific lipid profiles.

Pricing and reimbursement:

• Questran Light’s over-the-counter status in some regions simplifies access but impacts pricing strategies.
• Cost per treatment course averages around USD 25-30, significantly lower than PCSK9 inhibitors, which can exceed USD 10,000 annually.

What are the market projections going forward?

Forecasts predict modest growth for the bile acid sequestrant segment over the next five years, primarily driven by:

• Aging populations increasing the prevalence of hypercholesterolemia.
• Expanding indications for combination therapies in resistant cases.
• Regulatory guidance favoring non-statin options for patients intolerant to statins.

Revenue estimates:

• The segment is projected to grow at a compound annual growth rate (CAGR) of approximately 2-3% from 2023 to 2028.
• Questran Light’s sales are projected to remain stable or slightly decline as newer therapies supplant older agents in preference for their convenience and efficacy.

Market challenges:

• The emergence of PCSK9 inhibitors and novel lipid modifiers diminishes the share of traditional agents.
• Patient preference shifts toward oral, once-daily, more tolerable drugs.
• Patent expiration for underlying formulations leads to generic competition and pricing pressures.

What implications does this have for investment and R&D?

Limited clinical trial activity and market penetration suggest minimal near-term innovation interest in Questran Light. Companies investing in lipid management are focusing on biologics and advanced small molecules rather than reformulations of existing bile acid sequestrants. R&D efforts are aligned toward drug combinations and targeted therapies addressing resistant dyslipidemia and associated metabolic syndromes.

Investors should note that niche positions in older drug classes like Questran Light are unlikely to result in significant growth. However, the drug’s established safety profile and low cost may sustain a consistent if minor, market share among healthcare providers and patients.

Key Takeaways

• Questran Light has no active clinical trials and remains an approved, generic-based therapy for hypercholesterolemia.
• Market share is limited due to competition from newer lipid-lowering agents, especially PCSK9 inhibitors and combination therapies.
• The global hyperlipidemia treatment market is projected to grow modestly (2-3% CAGR), with Questran Light’s segment following this trend.
• Patent expiration and generic competition pressure its pricing and growth potential.
• Future innovations are unlikely to focus on reformulating Questran Light; research emphasizes biologics and combination regimens.

FAQs

1. Will Questran Light undergo new clinical trials?
Currently, no active investigations are known. The drug's patent has expired, and focus has shifted to newer agents.

2. Can Questran Light be used for indications other than lipid lowering?
No—its approved indication is hypercholesterolemia. Off-label use is not supported by current research.

3. How does Questran Light compare cost-wise with newer therapies?
It is significantly cheaper, averaging USD 25-30 per course, while PCSK9 inhibitors can cost over USD 10,000 per year.

4. What are the regulatory risks for Questran Light?
Since it is generic, it faces minimal regulatory hurdles unless new formulations or indications are pursued.

5. Is there potential for reformulation of Questran Light?
No active patent filings or trials suggest limited innovation interest in reformulating this agent.

---

References

1. ClinicalTrials.gov. "Questran Light Clinical Trials."
2. Global Market Insights. "Hyperlipidemia Treatment Market Analysis," 2022.
3. FDA. Drug Approval Reports.
4. IQVIA. Pharmaceutical Market Data, 2023.
5. EvaluatePharma. "Lipid-Lowering Market Forecast," 2022.